MYMasahito Yasuda

Masahito Yasuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masahito Yasuda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PD-L1 expression and possibility of its therapeutic target in cutaneous angiosarcoma.

    by Kyoichi Kaira, Akira Shimizu, Masahito Yasuda, Yuko Ohkubo, Takayuki Asao, Kenzo Takahashi, Osamu Ishikawa

    E23110 Background: Programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) targeting therapy have shown a promising survival benefit for patients with several human neoplasms. Cutaneous angiosarcoma (CA) is extremely rare neoplasma with a dismal outcome regardless of any treatments. However, it remains unclear whether the expression of PD-L1 is associated with any clinical and pathological variables in patients with CA. The aim of this study is to evaluate the clinicopathological significance of PD-L1 expression in CA. Methods: A total of 52 patients with CA patients were retrospectively reviewed. PD-L1, tumor proliferation determined by Ki-67 index and microvessel density determined by CD34, was evaluated immunohistochemically and correlated with the clinicopathological variables. Results: PD-L1 was positively expressed in 40% (21/52) of CA. The expression of PD-L1 was significantly associated with tumor cell proliferation determined by Ki-67 labeling index. Multivariate analysis confirmed that the positive expression of PD-L1 was identified as an independent factor to predict worse outcome. Conclusions: PD-L1 expression is a novel pathological marker for predicting worse outcome in CA patients. The inhibition of PD-L1 function may prevent tumor growth, providing us with a new effective therapeutic target of CA in future.


  • Safety and Efficacy of Topical Use of Imiquimod (Beselna Cream 5%) for the Treatment of Actinic Keratosis : A Retrospective Multicenter Collaborative Clinical Study

    by Masahito Yasuda, Etsuko Okada, Michiko Hasegawa, Yukie Endo, Keiichiro Ryuzaki, Katsuyuki Okada, Atsushi Tamura, Osamu Ishikawa

    日光角化症は,紫外線による表皮細胞の DNA 損傷から生じる表皮内癌であり,有棘細胞癌の早期病変である。近年,人口の高齢化とともにその発症数は増加してきており,早期治療が重要である。2011 年,日光角化症に対しイミキモド(ベセルナクリーム 5%)が保険適応疾患として追加承認された。日光角化症に対するイミキモド外用療法の有効性ならびに安全性を評価するために,2012年 6月から2013 年 6 月までイミキモドにより治療された日光角化症症例を解析する後ろ向き多施設共同臨床研究を行った。対象症例は 46 例,男性 23 例,女性 23 例,平均年齢は 82.2 歳,罹病期間の平均は 29.3 カ月であり,9 例に前治療歴があった。イミキモドは添付文書通りに使用されており,3 回/週で 4 週間外用,4 週間休薬し,効果不十分の場合はもう 1 コース追加された。奏効率は 78%,治療後 12 カ月まで観察できた 18 例では全例で再発はみられなかった。イミキモド外用による有害事象は,局所皮膚反応のみで,1 コース目では 47.8%,2 コース目では 8.7%にみられた。1 例は休薬する必要があったが,中止後速やかに改善していた。これまでの報告と同様,イミキモド外用は有効性が高く,再発率が低いことから,日光角化症に対して非常に有用な治療薬剤であると考える。


  • Primary cutaneous CD4+ small/medium T-cell lymphoma with aggressive clinical course

    by Masahito Yasuda, Naoya Igarashi, Yayoi Nagai, Atsushi Tamura, Osamu Ishikawa


  • The distinct autocrine PDGF signals in dermatofibrosarcoma protuberans can aid in differential diagnosis from other mesenchymal tumors

    by Ikumi Nakamura, Etsuko Okada, Masahito Yasuda, Kiyohito Taira, Osamu Ishikawa, Hiroshi Uezato, Kenzo Takahashi

    • 27 November 2004
      • Vol. 14  (6) , 379-82

    Genetic analyses of two cases of Werner's syndrome.

    by Yoko Sogabe, Masahito Yasuda, Yoko Yokoyama, Atsushi Tamura, Izumi Negishi, Kazunori Ohnishi, Tetsuya Shinozaki, Osamu Ishikawa

    We report two cases of Werner's syndrome (WS). First, a 42-year-old Japanese man was referred on suspicion of systemic sclerosis (SSc) because of scleroderma-like skin atrophy and foot ulcers. Second, a 51-year-old woman with malignant fibrous histiocytoma was referred on suspicion of premature aging syndrome. Because both patients had many typical manifestations compatible with WS, we made a clinical diagnosis of WS. Genetic analyses revealed a homozygous mutation, an A deletion at nucleotide 3677 of WS gene (WRN) in the first case and a homozygous mutation, a G to C substitution at one base upstream of exon 26 of WRN in the second case. Both mutations were consistent with those previously reported in Japanese WS patients.